Clinical Trial

A Phase I Study of KLA318-2 Nanocrystal Injection

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 26, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-05; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07171034
Lead Sponsor Hunan Kelun Pharmaceutical Co., Ltd.
Conditions Healthy Participants
Enrollment 48 participants
Start Date 2025-09-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26